New drug aims to supercharge immune system against tough cancers
NCT ID NCT06582017
First seen May 04, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the right dose, with a secondary look at whether it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sanai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact
-
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory University - Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Froedtert Hospital & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
New York Cancer & Blood Specialists
RECRUITINGNew York, New York, 11967, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute - Denver DDU
RECRUITINGDenver, Colorado, 80218, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rochester - Wilmot Cancer Institute
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Southern California
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QXL138AM (an antibody fused with an immune protein to target and attack cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for several hard-to-treat cancers, including ovarian, pancreatic, and multiple myeloma.
What could go wrong
This is a very early, first-in-human trial with only 100 participants. The drug may not be safe or effective, and side effects could be serious. Success is far from guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.